Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: Evidence for extrahepatic metabolism

Journal of Pharmaceutical Sciences

Volumn 94, Issue 10, 2005, Pages 2187-2197

  Koo, Tae Sung ^a   Kim, Dae Hyun ^a   Ahn, Sung Hoon ^a   Kim, Kang Pil ^a   Kim, In Wha ^a   Seo, Seung Yong ^a   Suh, Young Ger ^a   Kim, Dae Duk ^a   Shim, Chang Koo ^a   Chung, Suk Jae ^a  

^a Seoul National University   (South Korea)

Author keywords

Extrahepatic metabolism; Loxoprofen; Metabolism; Metabolite; NSAID; Pharmacokinetics

Indexed keywords

CARBONYL REDUCTASE; DRUG METABOLITE; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY FLUID; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MUSCLE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER HOMOGENATE; LIVER METABOLISM; MALE; MEAN RESIDENCE TIME; MUSCLE TISSUE; NONHUMAN; PLASMA; RAT;

EID: 27944484032     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20451     Document Type: Article

References (13)

1. Tanaka Y, Nishikawa Y, Hayashi R. 1983. Species differences in metabolism of sodium 2-[4-(2-oxocyclopenthylmethyl)-phenyl] propionate dehydrate (loxoprofen sodium), a new anti-inflammatory agent. Chem Pharm Bull 31:3656-3664.
2. Tanaka Y, Nishikawa Y, Matsuda K. 1984. Purification and some properties of ketone reductase forming an active metabolite of sodium 2-[4-(2- oxocyclopenthylmethyl)-phenyl]propionate dehydrate (loxoprofen sodium), a new anti-inflammatory agent, in rabbit liver cytosol. Chem Pharm Bull 32:1040-1048.
3. Sugimoto M, Kojima T, Asami M, Iizuka Y, Matsuda K. 1991. Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug. Biochem Pharmacol 42:2363-2358.
4. Kim IW, Choo KS, Han TG, Kim KS, Chung SJ, Lee MH, Shim CK. 2000. Decreased oral bioavailability of loxoprofen at second administration in human subjects. Int J Clin Pharmacol Ther 38: 10-14.
5. Choo KS, Kim IW, Jung JK, Suh YG, Chung SJ, Lee MH, Shim CK. 2001. Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method. J Pharm Biomed Anal 25:639-650.
6. Chae B, Jeon H, Lee S, Jeong N, Kim S, Cho K, Kim D. 1999. Anti-inflammatory and analgesic activity and plasma concentration of loxoprofen sodium plasters. J Appl Pharmacol 7:198-203.
7. Shchegolev AA. 1998. Parenteral use of oruvel (ketoprofen) for analgesia in the postoperative period. Anesteziol Reanimatol 5:35-37.
8. Nagashima H, Tanaka Y, Watanabe H, Hayashi R, Kasada K. 1984. Optical inversion of (2R)- to (2S)-isomers of 2-[4-(2-oxocyclopentylmethyl)-phenyl] propionic acid (loxoprofen), a new anti-inflammatory agent, and its monohydroxy metabolites in the rat. Chem Pharm Bull 32:251-257.
9. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd edn. New york: Marcel Dekker, Inc., 1-111.
10. Naruto S, Tanaka , Hayashi R, Terade A. 1984. Structural determination of rat urinary metabolites of sodium 2-[4-(2-oxocyclopenthylmethyl)-phenyl] propionate dehydrate (loxoprofen sodium), a new anti-inflammatory agent. Chem Pharm Bull 32:258-267.
11. Davies B, Mprris T. 1993. Physiological parameters in laboratory animals and human. Pharm Res 10:1093-1095.
12. Yamaguchi T, Kojima T, Kobayashi K, Endo Y, Misawa Y, Nakajima E, Misaka E, Tanaka K. 1983. CS-600, a new anti-inflammatory agent. II. Pharmacological efficacy and ulcerogenic effect of CS-600 and its active metabolites. Jpn Inflammation 3:63-67.
13. Kishimoto M, Kawamori R, Kamada T, Inaba T. 1994. Carbonyl reductase activity for acetohexamide in human erythrocytes. Drug Metab Dispos 22:367-370.